approval
saveSKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
community read0 votes
Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 202d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 202d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 214d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 214d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025 · 398d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025 · 398d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025 · 517d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025 · 517d ago
same company · ±60 days · 6
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalJan 14, 2022
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalDec 14, 2021
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalDec 14, 2021
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalDec 2, 2021
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalNov 30, 2021
- approvaldivalproex sodium DR: DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvalNov 30, 2021
comments(0)
5-min edit window · permanent after that